Please try another search
KPC Pharmaceuticals, Inc, a pharmaceutical company, engages in the research and development, production, marketing, and commercial wholesale of botanical drugs in the People’s Republic of China and internationally. It offers artemether, panax notoginseng, and gastrodine series drugs, as well as Chinese medicines and ethnic drugs under the Luotai, Tianxuanqing, Artemedine, Artem, and Arco brand names for treating cardio-cerebral-vascular and nervous system diseases, as well as malaria. The company also provides Dai medicines; antibiotics, chemical medicinal raw materials, chemical pharmaceutical preparations, traditional Chinese medicinal materials, biological products, biochemical drugs, and health foods; Amoxicillin, Cefaclor, Alfacalcidol, Artz, Snaplets, and Ribavirin spray products; glycyrrhizic acid; and GLP-1, a long-acting hypoglycemic drug. It markets artemisinin antimalarials, generic drugs, and medical apparatus. The company was formerly known as Kunming Pharmaceutical Corporation and changed its name to KPC Pharmaceuticals, Inc. in April 2015. The company was founded in 1951 and is based in Kunming, the People’s Republic of China.
Name | Age | Since | Title |
---|---|---|---|
Wensen Zhang | - | - | Supervisor |
Shuang You Li | 55 | 2015 | Vice Chairman |
Ke Liu | 71 | 2018 | Independent Director |
Jin Guo Xin | 61 | 2021 | Independent Director |
Xianggang Zhong | 47 | 2018 | President & Director |
Huawei Qiu | 54 | 2023 | Chairman |
Ting Guo | 48 | 2023 | Director |
Zheng Liang | 44 | 2023 | Director |
Li Lin Xi | 47 | 2018 | Employee Supervisor |
Zhang Weng Sen | 51 | 2018 | Employee Supervisor |
Zhi Yang | 61 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review